Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation

American Journal of Kidney Diseases

Volumn 40, Issue 5, 2002, Pages 1005-1012

  Tovbin, David ^a,b   Mazor, Dalia ^a,b   Vorobiov, Marina ^a,b   Chaimovitz, Cidio ^a,b   Meyerstein, Naomi ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Advanced oxidation protein products (AOPPs); Anemia; C reactive protein (CRP); Dityrosine; Hemodialysis (HD); Hydrogen peroxide; Hydroxyl radical; Inflammation; Intravenous iron (IVIR); Iron; Oxidative stress; Reactive oxygen species; Superoxide; Thiols

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCTS; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DITYROSINE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEPARIN; IRON; IRON POLYMALTOSE; IRON SACCHARATE; MELATONIN; PROTEIN; THIOL; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON THERAPY; KIDNEY FAILURE; MALE; OXIDATION; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL;

EID: 0036841986     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.36334     Document Type: Article

References (39)

1. Descamps-Latscha B, Witko-Sarsat V: Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 78:S108-S113, 2001
2. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
3. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407-414, 2001
4. Drueke TB, Khoa TN, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B: Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int 78:S114-S119, 2001 (suppl)
5. Handelman GJ, Walter MF, Adhikarla R, et al: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960-1966, 2001
6. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001
7. Mezzano D, Pais EO, Aranda E, et al: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60:1844-1850, 2001
8. Babior BM: Phagocytes and oxidative stress. Am J Med 109:33-44, 2000
9. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:1163-1169, 2001
10. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58:2571-2578, 2000
11. Himmelfarb J, McMonagle E: Manifestations of oxidant stress in uremia. Blood Purif 19:200-205, 2001
12. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
13. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333, 1997
14. Mocks J: Cardiovascular mortality in haemodialysis patients treated with epoetin beta-A retrospective study. Nephron 86:455-462, 2000
15. National Kidney Foundation: K/DOQI Clinical Practice Guidelines: Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001 (suppl 1)
16. Macdougall IC, Chandler G, Elston O, Harchowal J: Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 34:S40-S46, 1999 (suppl 2)
17. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am J Kidney Dis 37:300-307, 2001
18. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
19. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after IV ironsaccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
20. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin bound iron (NTBI) in dialysis patients. Eur J Clin Invest 32:42-49, 2002
21. Halliwell B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Its role in degradation of hyaluronic acid by a superoxide-generating system. FEBS Lett 96:238-242, 1978
22. Rooyakkers TM, Stroes ES, Kooistra MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32:9-16, 2002
23. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687, 1999
24. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
25. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37:750-757, 2001
26. Witko-Sarsat V, Descamps-Latscha B: Advanced oxidation protein products: Novel uremic toxins and proinflammatory mediators in chronic renal failure? Nephrol Dial Transplant 12:1310-1312, 1997
27. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
28. Witko-Sarsat V, Khoa TN, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products: Oxidative stress markers and mediators inflammation in uremia. Adv Nephrol Necker Hosp 28:321-341, 1998
29. Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358-363, 2001
30. Heinecke JW: Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 133:321-325, 1999
31. Heinecke JW, Li W, Daenke HL III, Goldstein JA: Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 268:4069-4077, 1993
32. Mio-Lin H: Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233:381-385, 1994
33. Rice-Evan C, Miller NJ: Total antioxidant status in plasma and body fluids. Methods Enzymol 234:279-293, 1994
34. Clermont G, Lecour S, Lahet J, et al: Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: A possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 47:618-623, 2000
35. Winterbourn CC, Peskin AV, Parsons-Mair HN: Thiol oxidase activity of copper, zinc-superoxide dismutase. J Biol Chem 277:1906-1911, 2001
36. Buxton GV, Greenstock CL, Helmon WP, Ross AB: Critical review of rate constants for reaction of hydrated electrons, hydrogen atoms and hydroxyl radicals in aqueous solution. J Phys Chem Ref Data 17:757, 1988
37. Mezyk SP: Determination of the rate constant for the reaction of hydroxyl and oxide radicals with cysteine in aqueous solution. Radiat Res 145:102-106, 1996
38. Gressier B, Cabanis A, Lebegue S, et al: Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: Comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol 16:9-13, 1994
39. Tovbin D, Markowitz A, Mostoslavsky M, Landver R: Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight. Clin Nephrol 53:276-282, 2000